Identification and Tracking of Antiviral Drug Combinations
Open Access
- 18 October 2020
- Vol. 12 (10), 1178
- https://doi.org/10.3390/v12101178
Abstract
Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.Keywords
Funding Information
- Estonian Research Competency Council (MOBTT39)
- National Research Foundation of Korea (NRF-2017M3A9G6068246)
This publication has 27 references indexed in Scilit:
- Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 ProteinsViruses, 2017
- SynergyFinder: a web application for analyzing drug combination dose–response matrix dataBioinformatics, 2017
- A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific MannerScientific Reports, 2017
- Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolismAntiviral Research, 2016
- JNJ872 inhibits influenza A virus replication without altering cellular antiviral responsesAntiviral Research, 2016
- Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic mannerAntiviral Research, 2016
- HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host speciesBMC Biotechnology, 2016
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- Molecular evolution and epidemiology of echovirus 6 in FinlandInfection, Genetics and Evolution, 2013
- Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro.2005